tiprankstipranks
Selectis Health (GBCS)
OTHER OTC:GBCS
US Market

Selectis Health (GBCS) AI Stock Analysis

Compare
4 Followers

Top Page

GBCS

Selectis Health

(OTC:GBCS)

Select Model
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-32.74% Downside)
Action:ReiteratedDate:11/19/25
The overall score of 43 for GBCS reflects significant financial instability as the primary concern, with negative profitability, high leverage, and weak cash flows weighing heavily. Technical indicators further support a bearish outlook with the stock below key moving averages. Valuation offers no positive offset due to unprofitability and lack of dividend yield.
Positive Factors
Revenue Growth
Despite financial challenges, the company demonstrates modest revenue growth, indicating potential for market expansion and product adoption.
Negative Factors
High Financial Leverage
Excessive leverage can strain financial stability, limiting the company's ability to invest in growth opportunities and weather economic downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Despite financial challenges, the company demonstrates modest revenue growth, indicating potential for market expansion and product adoption.
Read all positive factors

Selectis Health (GBCS) vs. SPDR S&P 500 ETF (SPY)

Selectis Health Business Overview & Revenue Model

Company Description
Global Healthcare REIT, Inc. (the "Company" or "Global") was organized with the intent of operating as a real estate investment trust (REIT) for the purpose of investing in real estate and other assets related to the healthcare industry. The Compa...
How the Company Makes Money
Selectis Health generates revenue through multiple channels, primarily by selling software licenses for its EHR systems and subscription fees for its telemedicine and patient engagement platforms. Additionally, the company earns income from consul...

Selectis Health Financial Statement Overview

Summary
Financial performance is weak with slight revenue growth of 2.12% but significant concerns including negative net profit margin (-7.61%), negative equity (-$6.4M), high leverage (debt-to-equity of -4.94), and negative cash flows (operating cash flow of -$693K). These factors indicate financial instability and operational challenges.
Income Statement
35
Negative
Balance Sheet
20
Very Negative
Cash Flow
25
Negative
BreakdownTTMDec 2024Dec 2023Dec 2022Mar 2022Mar 2021
Income Statement
Total Revenue42.17M39.49M36.78M40.60M29.29M20.93M
Gross Profit8.81M9.13M5.41M10.74M7.81M7.54M
EBITDA2.12M1.19M-7.29M1.51M1.00M4.96M
Net Income-787.66K-2.42M-3.97M-2.40M-2.25M2.96M
Balance Sheet
Total Assets33.26M33.45M40.67M42.49M46.92M45.93M
Cash, Cash Equivalents and Short-Term Investments417.13K680.33K1.48M1.42M3.96M3.59M
Total Debt31.23M32.23M37.25M37.89M38.50M39.50M
Total Liabilities38.92M38.86M43.64M41.54M43.82M42.72M
Stockholders Equity-5.65M-5.41M-2.96M952.84K3.10M3.41M
Cash Flow
Free Cash Flow804.86K-1.86M506.86K-527.51K-790.50K1.75M
Operating Cash Flow814.70K-1.82M536.67K-305.15K-270.93K2.73M
Investing Cash Flow-396.82K2.45M-29.80K-222.36K-519.58K-1.57M
Financing Cash Flow-1.02M-1.54M-618.74K-1.85M1.61M1.82M

Selectis Health Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.23
Price Trends
50DMA
3.16
Positive
100DMA
2.57
Positive
200DMA
2.36
Positive
Market Momentum
MACD
0.29
Negative
RSI
88.57
Negative
STOCH
89.88
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GBCS, the sentiment is Positive. The current price of 2.23 is below the 20-day moving average (MA) of 3.71, below the 50-day MA of 3.16, and below the 200-day MA of 2.36, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 88.57 is Negative, neither overbought nor oversold. The STOCH value of 89.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GBCS.

Selectis Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$1.38B23.4311.83%6.26%-19.33%
72
Outperform
$1.08B28.2310.87%29.89%10.33%
60
Neutral
$407.56M0.82-31.57%0.74%
52
Neutral
$729.93M-6.34-35.90%-11.42%-617.31%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
$12.48M-271.02-8.75%17.84%-156.13%
43
Neutral
$13.43M2.3913.38%10.10%85.20%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GBCS
Selectis Health
4.38
2.22
102.78%
AMS
American Shared Hospital Services
1.90
-0.88
-31.53%
AMN
AMN Healthcare Services
18.89
-4.61
-19.62%
CYH
Community Health
2.94
0.17
6.14%
HCSG
Healthcare Services
19.69
9.25
88.60%
PNTG
Pennant Group
31.11
6.31
25.44%

Selectis Health Corporate Events

Business Operations and StrategyExecutive/Board Changes
Selectis Health Adds Experienced Leaders to Board of Directors
Positive
Jan 6, 2026
Effective January 1, 2026, Selectis Health, Inc. appointed Kent J. Lund and former CEO Lance Baller to its Board of Directors, signaling a strategic move to deepen the board’s expertise in legal, compliance, and capital markets. Lund, a vete...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 19, 2025